Inflammatory markers predict survival in patients with postoperative urothelial carcinoma receiving tislelizumab (PD-1 inhibitor) adjuvant therapy

Abstract Background In the management of urothelial carcinoma, patient selection for immunotherapy, particularly with immune checkpoint inhibitors such as PD-1 (programmed cell death protein 1), is important for treatment efficacy. Inflammatory markers are useful for predicting treatment outcomes an...

Full description

Bibliographic Details

Published in:	BMC Cancer
Main Authors:	Meng Yang, Jingwen Zhang, Dongqun Wei, Tianyi Yu, Zeyu Chen, Xin Liu, Haitao Zhu
Format:	Article
Language:	English
Published:	BMC 2024-02-01
Subjects:	Immunotherapy Urothelial carcinoma Inflammatory markers Tislelizumab Survival
Online Access:	https://doi.org/10.1186/s12885-024-11969-5